Literature DB >> 25689972

Epidemiology of Huntington disease: first post-HTT gene analysis of prevalence in Italy.

F Squitieri1, A Griguoli1, G Capelli2, A Porcellini3, B D'Alessio4.   

Abstract

Huntington disease (HD) prevalence shows geographic variability and has been recently updated by taking into account the mutation diagnostic test. In Italy, the last epidemiological estimation was reported well before the HTT gene discovery and the availability of the corresponding genetic test. It reported a prevalence of affected subjects ranging between 2.3 and 4.8/100,000 in some restricted areas of Northern Italy. We have performed a service-based epidemiological analysis in a very restricted geographic area named Molise, where our institutions currently operate and represent the only point of reference for rare neuropsychiatric diseases. The estimated prevalence rate found was 10.85/100,000 (95% confidence interval (CI): 7.20-14.50), remarkably higher than that previously described before the gene test analysis was available, and expected to an increase of an additional 17% by 2030, because of Italian population aging. According to our analysis, we estimate that about 6500 subjects are currently affected by HD in Italy, and that this number will further increase in the next decades because of population aging, variable phenotype penetrance and improved life expectancy.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington disease; Italy; epidemiology; prevalence

Mesh:

Substances:

Year:  2015        PMID: 25689972     DOI: 10.1111/cge.12574

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

1.  Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.

Authors:  Priyanka Saroj; Yashika Bansal; Raghunath Singh; Ansab Akhtar; Rupinder Kaur Sodhi; Mahendra Bishnoi; Sangeeta Pilkhwal Sah; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2021-01-31       Impact factor: 4.473

2.  Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.

Authors:  Jin-Shei Lai; Siera Goodnight; Nancy R Downing; Rebecca E Ready; Jane S Paulsen; Anna L Kratz; Julie C Stout; Michael K McCormack; David Cella; Christopher Ross; Jenna Russell; Noelle E Carlozzi
Journal:  Qual Life Res       Date:  2017-12-08       Impact factor: 4.147

3.  Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.

Authors:  Weiqi Yang; Jingmo Xie; Qiang Qiang; Li Li; Xiang Lin; Yiqing Ren; Wenlei Ren; Qiong Liu; Guomin Zhou; Wenshi Wei; Hexige Saiyin; Lixiang Ma
Journal:  Neurosci Bull       Date:  2019-08-20       Impact factor: 5.203

4.  Sleep Quality and Related Clinical Manifestations in Huntington Disease.

Authors:  Sabrina Maffi; Eugenia Scaricamazza; Simone Migliore; Melissa Casella; Consuelo Ceccarelli; Ferdinando Squitieri
Journal:  J Pers Med       Date:  2022-05-25

5.  Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019).

Authors:  Hannah Furby; Suzanne Moore; Anna-Lena Nordstroem; Richard Houghton; Dimitra Lambrelli; Sophie Graham; Per Svenningsson; Åsa Petersén
Journal:  J Neurol       Date:  2022-10-18       Impact factor: 6.682

6.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

7.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

Review 8.  [Gene-selective treatment approaches for Huntington's disease].

Authors:  A Mühlbäck; K S Lindenberg; C Saft; J Priller; G B Landwehrmeyer
Journal:  Nervenarzt       Date:  2020-04       Impact factor: 1.214

Review 9.  Distribution of the HTT Gene A1 and A2 Haplotypes Worldwide: A Systematic Review.

Authors:  Thays Andrade Apolinário; Dionatan Costa Rodrigues; Mayra Braga Lemos; Carmen Lúcia Antão Paiva; Luciana Andrade Agostinho
Journal:  Clin Med Res       Date:  2020-09-02

10.  Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Angela Roberts; Praveen Dayalu; Dana L Hanifan; Jennifer A Miner; Daniel Claassen; Emily Mower Provost
Journal:  Qual Life Res       Date:  2020-08-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.